[1] |
Leidenius M, Leivonen M,Vironen J,et al. The consequences of longtime arm morbidity in node-negative breast cancer patients with sentinel node biopsy or axillary clearance [J]. J Surg Oncol, 2005,92(1):23-31.
|
[2] |
Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial [J]. J Natl Cancer Inst,2006,98(9):599-609.
|
[3] |
Rönkä R, von Smitten K, Tasmuth T, et al. One-year morbidity after sentinel node biopsy and breast surgery [J]. Breast,2005,14(1):28-36.
|
[4] |
Pavlista D, Eliska O. Analysis of direct oil contrast lymphography of upper limb lymphatics traversing the axilla—a lesson from the past—contribution to the concept of axillary reverse mapping [J]. Eur J Surg Oncol,2012,38(5):390-394.
|
[5] |
Sakorafas GH, Peros G, Cataliotti L, et al. Lymphedema following axillary lymph node dissection for breast cancer [J]. Surg Oncol,2006,15(3):153-165.
|
[6] |
Tausch C, Baege A, Dietrich D, et al. Can axillary reverse mapping avoid lymphedema in node positive breast cancer patients? [J]. Eur J Surg Oncol,2013,39(8):880-886.
|
[7] |
Ikeda K, Ogawa Y, Kajino C, et al. The influence of axillary reverse mapping related factors on lymphedema in breast cancer patients [J].Eur J Surg Oncol,2014,40(7):818-823.
|
[8] |
Noguchi M, Miura S, Morioka E, et al. Is axillary reverse mapping feasible in breast cancer patients? [J]. Eur J Surg Oncol,2015,41(4):442-449.
|
[9] |
Ngui NK, French J, Kilby CJ, et al. Axillary reverse mapping in patients with breast cancer: Is it oncologically safe? [J]. J Surg Oncol,2016,113(7):726-731.
|
[10] |
National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis,version. 1. 2010, 11/03/03 2009 [ M ]. Washington: National Comprehensive Cancer Network,Inc,2009:3.
|
[11] |
Bedrosian I, Babiera GV, Mittendorf EA, et al. A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients [J]. Cancer,2010,116(11):2543-2548.
|
[12] |
Rubio IT, Cebrecos I, Peg V, et al. Extensive nodal involvement increases the positivity of blue nodes in the axillary reverse mapping procedure in patients with breast cancer[J]. J Surg Oncol,2012,106(1):89-93.
|
[13] |
Ponzone R, Cont NT, Maggiorotto F, et al. Extensive nodal disease may impair axillary reverse mapping in patients with breast cancer [J].J Clin Oncol,2009,27(33):5547-5551.
|
[14] |
Gobardhan PD, Wijsman JH, van Dalen T, et al. ARM: axillary reverse mapping the need for selection of patients [J]. Eur J Surg Oncol,2012,38(8):657-661.
|
[15] |
Khandelwal R, Poovamma CU, Shilpy C, et al. Axillary reverse mapping: is it feasible in locally advanced breast cancer patients? [J].Breast Dis,2014,34(4):151-155.
|
[16] |
Schunemann E Jr, Doria MT, Silvestre JB, et al. Prospective study evaluating oncological safety of axillary reverse mapping [J]. Ann Surg Oncol,2014,21(7):2197-2202.
|
[17] |
刘坚,李佳璐,周俊,等.荧光法腋窝反向制图技术在乳腺癌手术中的可行性[J/CD]. 中华乳腺病杂志(电子版),2016,10(6):333-339.
|
[18] |
Pavlista D, Eliska O. Relationship between the lymphatic drainage of the breast and the upper extremity: a postmortem study [J]. Ann Surg Oncol,2012,19(11):3410-3415.
|